The potential impact of urine-LAM diagnostics on tuberculosis incidence and mortality: A modelling analysis.

ABSTRACT:

Background

Lateral flow urine lipoarabinomannan (LAM) tests could offer important new opportunities for the early detection of tuberculosis (TB). The currently licensed LAM test, Alere Determine TB LAM Ag ('LF-LAM'), performs best in the sickest people living with HIV (PLHIV). However, the technology continues to improve, with newer LAM tests, such as Fujifilm SILVAMP TB LAM ('SILVAMP-LAM') showing improved sensitivity, including amongst HIV-negative patients. It is important to anticipate the epidemiological impact that current and future LAM tests may have on TB incidence and mortality.

Methods and findings

Concentrating on South Africa, we examined the impact that widening LAM test eligibility would have on TB incidence and mortality. We developed a mathematical model of

SUBMITTER: Ricks S 

PROVIDER: S-EPMC7732057 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature